Role of Astrocytes in Manganese Neurotoxicity Revisited.

Role of Astrocytes in Manganese Neurotoxicity Revisited. Neurochem Res. 2019 Sep 30;: Authors: Ke T, Sidoryk-Wegrzynowicz M, Pajarillo E, Rizor A, Soares FAA, Lee E, Aschner M Abstract Manganese (Mn) overexposure is a public health concern due to its widespread industrial usage and the risk for environmental contamination. The clinical symptoms of Mn neurotoxicity, or manganism, share several pathological features of Parkinson's disease (PD). Biologically, Mn is an essential trace element, and Mn in the brain is preferentially localized in astrocytes. This review summarizes the role of astrocytes in Mn-induced neurotoxicity, specifically on the role of neurotransmitter recycling, neuroinflammation, and genetics. Mn overexposure can dysregulate astrocytic cycling of glutamine (Gln) and glutamate (Glu), which is the basis for Mn-induced excitotoxic neuronal injury. In addition, reactive astrocytes are important mediators of Mn-induced neuronal damage by potentiating neuroinflammation. Genetic studies, including those with Caenorhabditis elegans (C. elegans) have uncovered several genes associated with Mn neurotoxicity. Though we have yet to fully understand the role of astrocytes in the pathologic changes characteristic of manganism, significant strides have been made over the last two decades in deciphering the role of astrocytes in Mn-induced neurotoxicity and neurodegeneration. PMID: 31571097 [PubMed - as supplied by publisher]
Source: Neurochemical Research - Category: Neuroscience Authors: Tags: Neurochem Res Source Type: research

Related Links:

The above article was published online with incorrect author name. The right spelling should be Xiangming Wang instead of Xiangmin Wang. The correct name is presented here. The original article has been corrected.
Source: Neurological Sciences - Category: Neurology Source Type: research
Source: Neurological Sciences - Category: Neurology Source Type: research
The brain is an energy-hungry organ, and is sensitive to reductions in the blood supply of oxygen and nutrients. Cardiovascular aging can reduce that supply, whether through conditions such as heart failure, or the progressive loss of density in capillary networks that occurs throughout the body with advancing age, or an accelerated pace of rupture of tiny vessels in the brain, or disruption of the blood-brain barrier, allowing unwanted molecules and cells to enter the brain. Thus, as researchers here note, we would expect to see correlations between cardiovascular disease, or risk factors for cardiovascular disease, and d...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
In neurodegenerative conditions like Parkinson's disease, a specific group of neurons start to die one by one, causing movement problems and other symptoms. Scientists have long focused on finding out why these neurons die. Now it turns out, they might not even be dead.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
OBJECTIVES: Deteriorating functionality and loss of mobility, resulting from Parkinson's disease, may be worsened by osteoarthritis, which is the most common form of joint disease causing pain and functional impairment. We assessed the association between ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Introduction: The Munich Dysphagia Test for Parkinson's disease (MDT-PD) was initially developed and validated in the German population as a highly sensitive and specific self-reported screening questionnaire to detect early oropharyngeal symptoms and aspiration risk in patients with idiopathic Parkinson's disease (iPD). In order to make this tool accessible for prevention in the French speaking populations worldwide, we performed the first French translation and provide a linguistic and psychometric validation in the unique multilingual environment of the Luxembourg Parkinson's Study.Methods: We performed the translation ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
CONCLUSION: Dietary CQ10-supplementation was associated with demonstrable benefits in CPZ-induced Parkinsonism-like changes in mice. PMID: 31702498 [PubMed - as supplied by publisher]
Source: Current Aging Science - Category: Geriatrics Tags: Curr Aging Sci Source Type: research
Publication date: Available online 9 November 2019Source: NeuroImage: ClinicalAuthor(s): Komal Bharti, Antonio Suppa, Silvia Tommasin, Alessandro Zampogna, Sara Pietracupa, Alfredo Berardelli, Patrizia PantanoAbstractFreezing of gait (FOG) is a paroxysmal gait disorder that often occurs at advanced stages of Parkinson's disease (PD). FOG consists of abrupt walking interruption and severe difficulty in locomotion with an increased risk of falling. Pathophysiological mechanisms underpinning FOG in PD are still unclear. However, advanced MRI and nuclear medicine studies have gained relevant insights into the pathophysiology o...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
Conclusions: Symptomatic hip and knee osteoarthritis are risk factors for falls and related fractures among the elderly population with and without Parkinson's disease. The inability to walk 500 m could be used as a simple predictive factor for the increased risk of falls among elderly populations. PMID: 31700249 [PubMed]
Source: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders - Category: Orthopaedics Tags: Clin Med Insights Arthritis Musculoskelet Disord Source Type: research
Publication date: Available online 9 November 2019Source: Pharmacological ResearchAuthor(s): Yu Zhang, Qimei Wu, Lei Zhang, Qing Wang, Zexian Yang, Jia Liu, Linyin FengAbstractThe human A53 T mutant of α-synuclein tends to aggregate and leads to neurotoxicity in familial Parkinson's disease (PD). The aggregation of α-synuclein is also found in sporadic PD. Thus, targeting α-synuclein clearance could be used as a drug-discovery strategy for PD treatment. Caffeic acid (CA) has shown neuroprotection in Alzheimer's disease or cerebral ischaemia; however, it is unclear whether CA confers neuroprotection...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Environmental Health | Genetics | International Medicine & Public Health | Manganese | Neurology | Neuroscience | Parkinson's Disease | Study